As the pharmaceutical sector races to compress timelines and reduce risk, artificial intelligence is rapidly moving from experimental add-on to core infrastructure.
Dr Kev Robinson sat down with Chris McSpiritt (pictured), Vice President of Life Sciences Strategy at Domino Data Lab, to discuss the shifts he believes will define the industry by the end of 2026 — from autonomous design–make–test–analyse (DMTA) loops to AI-driven regulatory expectations.
Not yet a Subscriber?
This is a small extract of the full article which is available ONLY to premium content subscribers. Click below to get premium content on Manufacturing Chemist.
Subscribe now Already a subscriber? Sign in here.